Last updated on August 2018

Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer EGFR Activating Mutation Prior Treatment With a Tyrosine Kinase Inhibitor and Brain Metastases or Leptomeningeal Metastases

Brief description of study

A study to assess the activity of tesevatinib in subjects with NSCLC and activating EGFR mutations who have disease progression with Brain Metastases (BM) or Leptomeningeal Metastases (LM) or who heave either BM or LM at initial presentation.

Clinical Study Identifier: NCT02616393

Contact Investigators or Research Sites near you

Start Over

David Berz, MD

Beverly Hills Cancer Center
Beverly Hills, CA United States

Hatim Husain, MD

UC San Diego Moores Cancer Center
La Jolla, CA United States

Gina Tse, RN

USC/Norris Comprehensive Cancer Center
Los Angeles, CA United States

Kristy Massopust, CCRP

USC Norris Oncology/Hematology Newport Beach
Newport Beach, CA United States

Thierry Jahan, MD

University of California San Francisco
San Francisco, CA United States

Santosh Kesari, MD

John Wayne Cancer Institute
Santa Monica, CA United States

David Ross Camidge, MD, PhD

University of Colorado Cancer Center
Aurora, CO United States

Deepa Subramaniam, MD

Georgetown University Medical Center
Washington, WA United States

Melissa Johnson, MD

Sarah Cannon Research Institute
Nashville, TN United States

Barbara J O'Brien, MD

UT M.D. Anderson Cancer Center
Houston, TX United States